Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Furiex Pharmaceuticals, Inc. (FURX)
|
|
| Income Statement |
|
|
|
| Standardized | As Reported |
Annual | Quarterly | TTM |
|
| In millions, except per share items | Mar-31-14 | Dec-31-13 | Sep-30-13 | Jun-30-13 | Mar-31-13 | Dec-31-12 | Sep-30-12 | Jun-30-12 |
| | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q |
| Revenues: |
| Milestones | | | 10.0 | | 30.0 | | 10.0 | 10.0 |
| Royalties | 6.4 | | 5.6 | 3.0 | 9.3 | | 5.6 | 3.1 |
| Total revenues [+] | 6.4 | 13.1 | 15.6 | 3.0 | 39.3 | 9.2 | 15.6 | 13.1 |
| Licensing | | | 10.0 | | 30.0 | | 10.0 | 10.0 |
| Royalties | 6.4 | 8.1 | 5.6 | 3.0 | 9.3 | 9.2 | 5.6 | 3.1 |
| Revenue growth [+] | -83.7% | 42.6% | -0.2% | -77.1% | 1386.8% | 364.0% | 1124.6% | 1399.4% |
| Royalties | -31.1% | | -0.5% | -2.8% | 252.6% | | 338.4% | 252.6% |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 6.4 | 13.1 | 15.6 | 3.0 | 39.3 | 9.2 | 15.6 | 13.1 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Selling, general and administrative | 3.6 | 2.4 | 3.2 | 3.2 | 3.9 | 2.5 | 3.2 | 2.8 |
| Research and development | 14.3 | 15.4 | 19.9 | 22.1 | 25.4 | 14.6 | 14.8 | 30.8 |
| EBITDA [+] | -11.4 | -4.6 | -7.5 | -22.3 | 10.1 | -7.9 | -2.4 | -20.5 |
| EBITDA growth | -213.1% | -41.4% | 210.4% | 8.9% | -206.7% | 22.9% | -81.1% | 37.8% |
| EBITDA margin | -177.7% | -35.3% | -48.5% | -745.7% | 25.7% | -85.8% | -15.6% | -156.5% |
| Depreciation and amortization | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| EBIT [+] | -11.4 | -4.6 | -7.6 | -22.3 | 10.1 | -7.9 | -2.5 | -20.5 |
| EBIT growth | -213.4% | -41.5% | 207.9% | 8.9% | -206.2% | 22.9% | -80.9% | 37.7% |
| EBIT margin | -177.8% | -35.3% | -48.6% | -746.3% | 25.6% | -86.0% | -15.7% | -156.7% |
| Interest expense | 1.6 | 1.7 | 1.1 | 1.1 | 1.1 | 1.1 | 0.8 | 0.3 |
| Interest expense | 1.6 | 1.7 | 1.1 | 1.1 | 1.1 | 1.1 | 0.8 | 0.3 |
| Other income (expense), net | 0.0 | | | 0.0 | 0.1 | 0.0 | | |
| Pre-tax income | -13.0 | -6.3 | -8.7 | -23.4 | 9.1 | -9.0 | -3.3 | -20.8 |
| Income taxes | 0.0 | 0.2 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 |
| Tax rate | | | | | 1.0% | | 0.1% | |
| Net income | -13.1 | -6.5 | -8.7 | -23.5 | 9.0 | -9.1 | -3.3 | -20.8 |
| Net margin | -203.2% | -49.5% | -55.8% | -784.4% | 22.8% | -98.3% | -21.1% | -158.8% |
| |
| Basic EPS [+] | ($1.25) | ($0.64) | ($0.85) | ($2.32) | $0.89 | ($0.91) | ($0.33) | ($2.09) |
| Growth | -239.9% | -29.4% | 160.1% | 11.1% | -191.1% | 33.3% | -75.1% | 38.5% |
| Diluted EPS [+] | ($1.25) | ($0.64) | ($0.85) | ($2.32) | $0.82 | ($0.91) | ($0.33) | ($2.09) |
| Growth | -251.6% | -29.4% | 160.1% | 11.1% | -184.1% | 33.3% | -75.1% | 38.5% |
| |
| Shares outstanding (basic) [+] | 10.4 | 10.1 | 10.2 | 10.1 | 10.0 | 10.0 | 10.0 | 10.0 |
| Growth | 4.0% | 1.6% | 1.6% | 1.6% | 0.9% | 1.0% | 1.4% | 0.8% |
| Shares outstanding (diluted) [+] | 10.4 | 10.1 | 10.2 | 10.1 | 10.9 | 10.0 | 10.0 | 10.0 |
| Growth | -4.0% | 1.6% | 1.6% | 1.6% | 9.3% | 1.0% | 1.4% | 0.8% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|